Celltrion showcases positive one-year results for subcutaneous formulation of infliximab in patients with active Crohn’s disease and ulcerative colitis

Celltrion showcases positive one-year results for subcutaneous formulation of infliximab in patients with active Crohn’s disease and ulcerative colitis. (Credit: Belova59 from Pixabay)